C. Light Technologies赢得了罗氏的MS挑战，资助了一项为期两年的眼动追踪技术早期多发性硬化症进展试验。 C. Light Technologies wins Roche’s MS challenge, funding a 2-year trial using eye-tracking tech to detect early MS progression.

C. 为Roche的MS创新挑战选择了轻型技术,获得资金与UCSF和Sutter Health一起发起为期两年的临床试验。 C. Light Technologies has been chosen for Roche’s MS Innovation Challenge, receiving funding to launch a two-year clinical trial with UCSF and Sutter Health. 这项研究将利用其经林业发展局批准的RetitractTM技术,测量固定眼部运动——短暂的、非自愿的动作——作为非侵入性生物标志,用于多发性硬化症,特别是在没有复发的情况下(PIRA)。 The study will use its FDA-cleared Retitrack™ technology to measure fixational eye movements—tiny, involuntary motions—as non-invasive biomarkers for multiple sclerosis progression, especially in cases without relapses (PIRA). 在五个时点进行10秒的非侵入扫描,目的是在残疾出现在标准工具,如EDSS或MRI上之前,发现早期疾病变化。 The 10-second, non-invasive scans, performed at five timepoints, aim to detect early disease changes before disability appears on standard tools like EDSS or MRI. 美国医学协会核准了新的CPT(1010T)视网膜跟踪代码,自2026年1月1日起生效,可能使保险偿还成为可能。 The American Medical Association approved a new CPT code (1010T) for retinal eye tracking, effective January 1, 2026, potentially enabling insurance reimbursement. 该公司筹集了800多万美元,包括一个300万美元的种子推广回合,并正在推广AI动力检测神经退化性疾病的工具。 The company has raised over $8 million, including a $3 million seed extension round, and is advancing AI-powered detection tools for neurodegenerative diseases.